menu toggle

Integrating biosimilars into health systems pharmacies

By IHOC

Biosimilars are reshaping the treatment landscape for biologic-based therapies. In addition to producing clinically-equivalent outcomes to their reference products, studies show biosimilars will contribute to lowering the overall cost of healthcare.

To help Pharmacy & Therapeutics (P&T) committees determine whether biosimilars are appropriate for their health system’s formulary, pharmacy leaders will need to help address three current barriers to adoption: physician support, operational concerns and potential economic considerations.

To read the full article, as originally published in Becker's Hospital Review, click here.

Related Content

3 Key Considerations for Implementing Biosimilars in Health Systems

Inverted color AmerisourceBergen icon
IHOC
September 2018

Rick Lozano, vice president of biosimilars and integrated business development for AmerisourceBergen, shares the three considerations for implementing biosimilars in the health system setting.

Supply chain tip of the day: Understand biosimilar nuances before integrating them into the system

Inverted color AmerisourceBergen icon
IHOC
December 2018

Biosimilars are creating new cost-saving opportunities for health system pharmacies, but before pharmacy leaders integrate biosimilars into their health system, they must understand their nuances.

Biosimilars: Strategies for Utilization in the Health System Setting

Inverted color AmerisourceBergen icon
IHOC
August 2018

As biosimilars enter the market, they have the potential to reshape the treatment landscape. In this informative webinar, leading experts will share how these options create opportunities for health system pharmacy leaders.